A pragmatic guide to choosing biologic therapies in severe asthma

There are now several monoclonal antibody (mAb) therapies (“biologics”) available to treat severe asthma. Omalizumab is an anti-IgE mAb and is licensed in severe allergic asthma. Current evidence suggests it may decrease exacerbations by augmenting deficient antiviral immune responses in asthma. Lik...

Descripción completa

Detalles Bibliográficos
Autores principales: Kavanagh, Joanne E., Hearn, Andrew P., Jackson, David J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919802/
https://www.ncbi.nlm.nih.gov/pubmed/35296105
http://dx.doi.org/10.1183/20734735.0144-2021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919802/
https://www.ncbi.nlm.nih.gov/pubmed/35296105
http://dx.doi.org/10.1183/20734735.0144-2021

Ejemplares similares